Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 10/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528526 | 0.87 | RXFP1 (0.70) | SMN1; SMN2RXFP1RXFP2 | |
| SCHEMBL15528361 | 0.86 | RXFP1 (0.72) | ALDH1A1RXFP1KDM4EHPGDNPSR1 | |
| SCHEMBL15528295 | 0.86 | RXFP1 (0.75) | ALDH1A1RXFP1KDM4EHPGDNPSR1 | |
| SCHEMBL15528839 | 0.84 | RXFP1 (0.76) | ALDH1A1RXFP1RXFP2LMNA | |
| SCHEMBL15528386 | 0.84 | RXFP1 (0.72) | ALDH1A1RXFP1KDM4EHPGDNPSR1 | |
| SCHEMBL15528697 | 0.83 | RXFP1 (0.79) | ALDH1A1RAB9ARXFP1KDM4EHPGD | |
| SCHEMBL3188745 | 0.83 | ENPP3 (0.69) | MEN1KMT2ARAB9AHPGD | |
| SCHEMBL5205624 | 0.82 | NPC1 (0.69) | MEN1KMT2ARAB9AHPGD | |
| SCHEMBL5223733 | 0.81 | F10 (0.60) | ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL15530329 | 0.81 | RXFP1 (1.00) | ALDH1A1RXFP1RXFP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844345-B1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | US HEALTH (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10125112-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| EP-2844345-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | The United States of America, as Represented by The Secretary, Department of Health and Human Services (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013165606-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | ALDH1A1 2561/4885MEN1 687/4885KMT2A 4449/4885 |
| US-10125112-B2 | Modulators of the relaxin receptor 1 | RXFP1, RXFP2, RXFP3 | ALDH1A1 2561/4885MEN1 687/4885KMT2A 4449/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | ALDH1A1 2561/4885MEN1 687/4885KMT2A 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.